Today, we’re excited to announce a groundbreaking new partnership with Phenomix Sciences, a precision medicine biotechnology company that applies data intelligence to the treatment of obesity. The collaboration integrates Phenomix’s MyPhenomeTM genetic obesity test with InformedDNA’s DNAimpactTM precision health platform, broadening access to genetics-based weight management care for payers, health systems, employers, and life sciences organizations.
Patient response to anti-obesity medications is highly variable and unrelated to current assessable characteristics like age, BMI, race, or comorbidities. Phenomix’s MyPhenome test is a simple saliva test that helps care providers better understand the underlying biology and genetics of obesity so they can match patients with the right obesity treatments, including GLP-1s. Studies have shown obesity treatments tailored to a patient’s biological traits and identified through the MyPhenome tests are twice as effective as other one-size-fits-all treatments.
Through the DNAimpact Metabolic program, InformedDNA genetics experts will use the MyPhenome test to guide people through the simple saliva test process, the comprehensive test report that offers personalized context behind the cause of their obesity, and continued care throughout their weight-loss journey. The test results will help practitioners develop precise and effective treatment plans, including lifestyle and diet intervention, as well as medication and/or procedure recommendations specific to that patient’s genetics.
This partnership, along with new offerings like our DNAimpact Metabolic module, is empowering patients and providers with personalized health solutions tailored to each individual’s genetic makeup to drive better outcomes. We are excited to continue expanding our work with stakeholders like Phenomix and others across the spectrum who share our desire to ensure that the right therapeutic options, such as GLP-1’s, are targeted to those most likely to derive benefit according to their genetic profile and associated phenotype.
You can view today’s announcement here. For more specifics on access to the MyPhenome test or the DNAimpact Metabolic program, contact metabolic@informeddna.com.
